Silver Book Fact

Life expectancy and quality of life gains from AVR

A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years gained at a net value of $11.2 billion (~$14.2 billion in 2017 dollars).

Wu Y, Grunkmeier G, Starr A. The Value of Aortic Valve Replacement in Elderly Patients: An economic analysis. J Thorac Cardiovasc Surg. 2007; 133(3): 603-7. http://www.jtcvsonline.org/article/S0022-5223(06)01477-2/fulltext

Reference

Title
The Value of Aortic Valve Replacement in Elderly Patients: An economic analysis
Publication
J Thorac Cardiovasc Surg
Publication Date
2007
Authors
Wu Y, Grunkmeier G, Starr A
Volume & Issue
Volume 133, Issue 3
Pages
603-7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • In 2010, ~67,500 SAVRs were performed in the U.S.
     
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…